|
Baseline ejection fraction group
|
56%-62%
|
63%-70%
|
|---|
|
N
|
109
|
216
|
|
Age
|
26.6 (8.6)
|
26.6 (8.7)
|
|
Sex
| | |
|
Male N (%)
|
59 (54.1)
|
110 (53.4)
|
|
Female N (%)
|
50 (45.9)
|
96 (46.6)
|
|
Ethnicity
| | |
|
Indian N (%)
|
31 (28.4)
|
56 (27.2)
|
|
Greek N (%)
|
18 (16.5)
|
31 (15.1)
|
|
Cypriot N (%)
|
17 (15.6)
|
30 (14.6)
|
|
Pakistani/Bangladeshi N (%)
|
14 (12.8)
|
32 (14.8)
|
|
Turkish/Arabic N (%)
|
12 (11.0)
|
18 (8.3)
|
|
Italian/Romanian N (%)
|
6 (5.5)
|
12 (5.6)
|
|
Chinese/Malay N (%)
|
5 (4.6)
|
4 (2.0)
|
|
Unknown N (%)
|
7 (6.4)
|
20 (9.3)
|
|
Ferritin [ug/L]
|
2140 (1600)
|
2065 (1636)
|
|
Cardiac T2* [ms]
|
19.7 (13.3)
|
23.2 (13.8)
|
|
Liver T2* [ms]
|
4.5 (4.3)
|
5.1 (4.6)
|
|
LVEDV [mL]
|
132.1 (33.5)
|
128.3 (38.4)
|
|
LVESV [mL]
|
49.3 (19.9)
|
43.8 (19.0)
|
|
LVEF [%]
|
59.7 (1.8)
|
66.7 (2.3)
|
|
Treatment
| | |
|
DFO N (%)
|
72 (66.1)
|
109 (52.9)
|
|
DFP N (%)
|
10 (9.2)
|
35 (17.0)
|
|
DFX N (%)
|
3 (2.75)
|
6 (2.9)
|
|
DFO + DFP N (%)
|
22 (20.2)
|
50 (24.3)
|
|
DFO + DFX N (%)
|
1 (0.9)
|
0 (0)
|
|
None N (%)
|
1 (0.9)
|
6 (2.9)
|
- shown as mean (SD) except where N (%) is shown
- LV-left ventricle, EDV-end-diastolic volume, ESV-end-systolic volume, EF-ejection fraction, DFO-deferoxamine, DFP-deferiprone, DFX-deferasirox.
